US20230201294A1 - Aqueous extraction process of plants, method thereof, and product by process - Google Patents
Aqueous extraction process of plants, method thereof, and product by process Download PDFInfo
- Publication number
- US20230201294A1 US20230201294A1 US18/115,927 US202318115927A US2023201294A1 US 20230201294 A1 US20230201294 A1 US 20230201294A1 US 202318115927 A US202318115927 A US 202318115927A US 2023201294 A1 US2023201294 A1 US 2023201294A1
- Authority
- US
- United States
- Prior art keywords
- extraction
- cells
- epe001
- mixture
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 103
- 238000000034 method Methods 0.000 title claims description 28
- 230000008569 process Effects 0.000 title description 13
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 239000006286 aqueous extract Substances 0.000 claims abstract description 10
- 240000005528 Arctium lappa Species 0.000 claims abstract description 8
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 8
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 8
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 8
- 240000005979 Hordeum vulgare Species 0.000 claims abstract description 8
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 8
- 244000167230 Lonicera japonica Species 0.000 claims abstract description 8
- 235000017617 Lonicera japonica Nutrition 0.000 claims abstract description 8
- 235000019057 Raphanus caudatus Nutrition 0.000 claims abstract description 8
- 244000088415 Raphanus sativus Species 0.000 claims abstract description 8
- 235000011380 Raphanus sativus Nutrition 0.000 claims abstract description 8
- 235000006533 astragalus Nutrition 0.000 claims abstract description 8
- 206010061218 Inflammation Diseases 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 201000004384 Alopecia Diseases 0.000 claims abstract description 3
- 230000003676 hair loss Effects 0.000 claims abstract description 3
- 208000024963 hair loss Diseases 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims description 7
- 235000001667 Vitex agnus castus Nutrition 0.000 claims description 7
- 244000063464 Vitex agnus-castus Species 0.000 claims description 7
- 235000009347 chasteberry Nutrition 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 210000002919 epithelial cell Anatomy 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000003039 volatile agent Substances 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 28
- 239000000126 substance Substances 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000003779 hair growth Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 241001643642 Viticis Species 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- 239000008213 purified water Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000003559 RNA-seq method Methods 0.000 description 8
- 239000004745 nonwoven fabric Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000001223 reverse osmosis Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000003068 pathway analysis Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 101710170054 Nuclear protein 1 Proteins 0.000 description 2
- 102100021133 Nuclear protein 1 Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 2
- 108010049224 perlecan Proteins 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- KRZBCHWVBQOTNZ-UHFFFAOYSA-N (-) 3,5-dicaffeoyl-muco-quinic acid Natural products OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-UHFFFAOYSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-RDJMKVHDSA-M (-)-3,5-Dicaffeoyl quinic acid Natural products O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C([O-])=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-M 0.000 description 1
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 description 1
- 241001084338 Listeria sp. Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- PJQLSMYMOKWUJG-UHFFFAOYSA-N casticin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(OC)C=C2O1 PJQLSMYMOKWUJG-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000025611 cell-substrate adhesion Effects 0.000 description 1
- CCWSQXBMKLEALQ-WMZOPIPTSA-N centaureidin Natural products CO[C@@H]1[C@@H](Oc2cc(O)c(OC)c(O)c2C1=O)c3ccc(OC)c(O)c3 CCWSQXBMKLEALQ-WMZOPIPTSA-N 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- DTPRTOXMYKYSIJ-UHFFFAOYSA-N eupatorin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC(OC)=C(OC)C=C2O1 DTPRTOXMYKYSIJ-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000020129 regulation of cell death Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- HKMZDYJMJDPXRP-UHFFFAOYSA-N vitexicarpin Natural products OC1=C2C(C(=C(OC2=CC(=C1OC)OC)C1=CC(=CC(=C1)OC)O)OC)=O HKMZDYJMJDPXRP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Definitions
- the present invention relates generally to an aqueous extraction process and method for use thereof, and more specifically to an aqueous extraction process of specific plants for the chemical composition thereof.
- the present invention generally provides for the preparation of an aqueous extract resulting from an aqueous extraction of individual or mixtures of Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare and the chemical composition comprising said extracts or fractions thereof, and the use of said compositions or fractions thereof for treating or preventing cancers and inflammation related diseases, hair loss, stimulating hair growth, increasing energy production, and boosting immunity.
- the resulting extracts include a mixture of naturally occurring biologically active phytochemical compounds that possess a variety of beneficial animal and human health effects.
- FIG. 1 is a diagram of a preferred embodiment static (batch) aqueous extraction system.
- FIG. 2 is a diagram of an alternative embodiment dynamic (semi-continuous flow) aqueous extraction system.
- FIG. 3 is a LC-MS chromatogram depicting the components of an exemplary product (EPE001) of an extraction process utilizing one of the embodiments of the extraction systems of FIGS. 1 and 2 .
- FIG. 4 is a bar graph depicting results of a treatment of human breast cancer cells utilizing a product produced by the process resulting from the embodiments of either FIG. 1 or FIG. 2 .
- FIG. 5 shows a series of cells taken through a microscope on day 5 of the bar graph of FIG. 4 .
- FIG. 6 is a bar graph depicting results of a treatment of human epithelial cells utilizing a product produced by the process resulting from the embodiments of either FIG. 1 or FIG. 2 .
- FIG. 7 shows a series of cells taken through a microscope on day 5 of the bar graph of FIG. 6 .
- FIG. 8 is a bar graph depicting results of a treatment of fibroblast cells utilizing a product produced by the process resulting from the embodiments of either FIG. 1 or FIG. 2 .
- FIG. 9 shows a series of cells taken through a microscope on day 5 of the bar graph of FIG. 8 .
- FIG. 10 is a table including a summary of gene expression changes in the presence of an exemplary product of the extraction process (EPE001) using RNA-Seq analysis.
- FIG. 11 is a table including a summary of diseases and associated networks that are affected as a result in upregulation or downregulation of the summary from the RNA-Seq analysis.
- FIG. 1 shows a static aqueous extraction system 2 .
- a process utilizing this static system 2 results in a product capable of producing desired results as described in more detail and in specific examples below.
- Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare are combined in equal or various amounts by dry weight and placed in a spunbond nonwoven fabric container 14 .
- the fabric container may be placed upon a pedestal 16 within the extraction apparatus 8 for optimal results.
- the spunbond nonwoven fabric container 14 is sealed and then fixed within the extraction apparatus 8 containing reverse-osmosis membrane filtered purified or distilled water 10 as shown in FIG. 1 .
- the extraction apparatus may be made of a stainless steel or glass vessel.
- the extraction apparatus 8 is contained within a heating element 6 .
- the extraction apparatus is closed and sealed with a seal 12 and then heated such that the water 10 is boiling for 3-6 hrs. Some of the vapor is discharged through the water-cooled condenser outlet 4 affixed to the top of the extraction apparatus 8 allowing some volatiles to escape while retaining a portion that are condensed and returned to the extraction apparatus.
- the seal retains the condenser unit 4 in connection with the extraction apparatus 8 .
- the resulting extraction mixture is then filtered in succession using a membrane filter with a pore size not bigger than 10-6 m (1 micron) and purified water at 90-100° C., 70-85° C., 40-60° C., 15-30° C., and 5-15° C., providing the final product filtrate (extract) that contains ⁇ 370 mg of biologically active solid ingredients per liter of aqueous extract.
- Example compounds identified in the aqueous extract include acids such a chlorogenic and cinnamic acid, aldehydes, e.g. cinnamaldehyde and lignans, e.g. archin.
- Cinnamomum cassia for each liter of water, 220 mg of Cinnamomum cassia, 110 mg Arctium lappa, 220 mg Vitex agnus castus, 110 mg Lonicera japonica, 110 mg Acanthopanax gracilistylis, 110 mg Raphanus sativus, 110 mg Astragalus membranaceus and 220 mg Hordeum vulgare are combined and placed in a spunbond nonwoven fabric, and the spunbond nonwoven fabric sealed and then fixed within the extraction apparatus filled with reverse-osmosis membrane filter purified or distilled water. The extraction vessel is closed and then heated to boiling for 3 hrs.
- EPE001 hot extraction mixture, of these ingredients is referred to as, EPE001, from this point onward, is then filtered in succession via simple vacuum assisted filtration using membrane filters with a pore size not bigger than 10-6 m (1 micron) at 90-100° C., 70-85° C., 40-60° C., 15-30° C., and 5-15° C. providing the final product extract that contains ⁇ 370 mg of biologically active solid ingredients per liter of aqueous extract.
- FIG. 2 presents an alternative system for producing a chemical compound from an aqueous extraction process utilizing a dynamic system 52 .
- a dynamic system 52 In the same manner as the static system 2 , an individual herb or a desired mixture of Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare, are combined in equal or various amounts by dry weight and placed in a spunbond nonwoven fabric container 14 , and the spunbond nonwoven fabric container 14 is sealed and then fixed within the extraction vessel 8 .
- Reverse-osmosis membrane filter purified, or distilled water 10 is then pumped into the extraction vessel 8 via a pump 20 .
- the extraction apparatus 8 is contained within a heating element 6 .
- the extraction apparatus is closed and sealed with a seal 12 and heated to boiling for 4-6 hrs. Some of the vapor is discharged through the water-cooled condenser outlet 4 affixed to the top of the extraction vessel allowing some volatiles to escape while retaining some that are condensed and returned to the extraction vessel.
- the resulting extraction mixture, EPE001 is then filtered in succession by pressure driven filtration using filters with a pore size not bigger than 10-6 m (1 micron) utilizing a system of appropriately connected pumps and valves that allow for efficient transfer of the purified water extract at 70-95° C., followed by filtering the extract using purified water at 70-95° C., 40-60° C., 15-30° C., and 5-15° C., providing the final product extract that contains ⁇ 350 mg of active solid ingredients per liter of aqueous extract.
- This extraction process allows for a dynamic semi-continuous flow production of biologically active extract by pausing the process, recharging the spunbond nonwoven fabric with selected amounts of dried herbs and initiating the process by pumping purified water 10 into the extraction vessel 8 and restarting the heating device.
- This process is made dynamic through the use of a large vessel of purified water 18 which is pumped using a pump 20 into the extraction vessel 8 . It is then pulled out of the extraction vessel 8 using a series of valves 22 , filters 24 , and pumps 20 as shown in FIG. 2 into one or more storage containers 26 , 26 . 1 , 26 . 2 , 26 . 3 .
- the system can be run dynamically until all storage containers are filled, and as soon as there is volume in one storage container as shown, the aqueous extraction can pass onto the next pump and filter set.
- Purified water can be pumped into the vessel 8 from the reservoir 18 through an inlet in the reservoir near the top of the vessel.
- the aqueous extract can be pumped out through an outlet near the bottom of the vessel and through a single or series of decreasing pore-size filters with the final filter being a 0.2 ⁇ m filter.
- the filtrate would then be dispensed into a collection vessel as a finished product for a number of various uses.
- a first use of the extract would be as a potential cancer therapeutic. This would provide an application to a broad range of solid cancers (neoplasias) due to effects of the extract chemical composition on mitochondrial function in cancer cells (e.g. apoptosis, autophagy, and mitochondrial membrane potential changes) as well as changes in transcriptional activation (promote or inhibit) of key genes associated with cancer progression or suppression.
- the benefits include a reduction or elimination of side effects common in existing cancer therapeutics.
- the preparation of the extract as presented herein provides for the delivery of biologically active compounds topically or as an aqueous oral dose. It has a bioactivation and bioavailability increase upon digestion associated with changes in pH. It causes a decrease in the proliferation of cancer cells and an inhibition of genes related to cancer cell growth.
- a second use of the extract as presented herein would be an anti-inflammatory therapeutic. It provides a reduction in reactive oxygen species formation in normal cells. It reduces production of inflammatory cytokines. It also provides increased mobility with concurrent decrease in joint pain.
- a third use is as an energy supplement.
- the extract provides an increase in beta-oxidation utilizing fatty acids as a substrate for generation of ATP. It provides increased energy production (e.g. mitochondrial efficiency). It also provides a decrease in glucose dependency as a metabolic substrate, while also reducing inflammation as described above.
- a fourth use is as a weight loss supplement.
- the extract has been shown to increase beta-oxidation utilizing fatty acids as a substrate for generation of ATP. and a decrease in glucose dependency as a metabolic substrate.
- the extract has also been shown to decrease glucose dependency as a metabolic substrate. These metabolic changes are expected to cause weight loss.
- the extract has also been shown to provide an inhibition of some known obesity related gene expression.
- a fifth use is for its antiviral effectiveness due to increased potential cell membrane resistance and decreased replication capabilities against clinically relevant viral strains including HIV, Influenza Virus, West Nile Virus, Adenovirus, and Polymavirus.
- a sixth use is for its antimicrobial effectiveness due to its effectiveness against pathogenic bacterial infections including, Streptococcus sp., Staphylococcus sp., and Listeria sp.
- a seventh use is for dermatological stem cell activity, such as for use for hair growth or other uses against skin conditions such as atopic dermatitis, psoriasis, and eczema.
- An eighth use is for boosting the immune system. Specifically, inducing pluripotent stem cells to replace depleted populations of T-cell lymphocytes. This population replenishment has direct positive benefits in the mechanism of action and is described in [0027] and [0028].
- FIGS. 3 - 9 show several examples and results thereof utilizing a product produced by the processes described above. Other examples are not explicitly shown, but the results are described below.
- Typical treatments for cancer involve chemicals that are not only toxic to infected cells but also other surrounding cells, tissues and systems. Because of this there is a growing need and interest for utilizing natural products for treatment of a variety of human diseases and conditions. Using the herein described process, a reproducible, aqueous extract of a combination of plants has been shown to be toxic to human cultured cancer cells but does not harm healthy cells.
- each of the eight herbs Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare ) were milled to a powder then passed through a 0.21 mm mesh sieve to exclude any large particulates.
- the powders were combined and placed into a spunbond nonwoven fabric bag and sealed then placed into a vessel containing reverse-osmosis purified water utilizing the static system 2 shown in FIG. 1 and alternatively the dynamic continuous system 52 shown in FIG. 2 . After the vessel was sealed, the water was brought to a boil for 3 hours.
- the aqueous extract (EPE001) was split into four aliquots. Two aliquots were cooled to 80° C. before passing through either a qualitative filter (11 ⁇ m) or a 0.2 ⁇ m filter. The other two aliquots were allowed to cool to room temperature before being passed through either a qualitative filter (11 ⁇ m) or a 0.2 ⁇ m filter. A portion of each aliquot was lyophilized to dryness before being diluted with purified water to a final concentration of 3.6 mg extract residue per milliliter. Each of these samples were then utilized in analytical experimentation and bioassays to determine chemical composition and biological activity
- FIG. 3 shows a graph wherein each of the four samples were analyzed using a Waters ACQUITY UPLC-PDA-MS system.
- Major components were identified by mass, then verified through comparison to a prepared standard of the isolated molecule to confirm the identity.
- Major components of the extract are: arctigenin, cholorgenic acid, neocholorgenic acid, isochlorogenic acid A, arctiin, quercetin 3-O- ⁇ -D glucoside, cyanarin and casticin. Other components of the extract have not yet been identified.
- Sample collected from the extraction process was lyophilized to dryness and resuspended to a final concentration of 3.6 mg/mL in 0.1% formic acid (pH 4.2).
- Chromatography was achieved using a 20 ⁇ L injection volume and a Waters ACQUITY UPLC HSS T3, 100 ⁇ , 2.1 ⁇ 100 mm, column. A gradient elution was used with Mobile Phase A of 0.1% formic acid (pH 4.2) and Mobile Phase B of 80:20 acetonitrile: water. The linear chromatographic gradient started with 95% Mobile Phase A and concluded with 5% Mobile Phase A over 19.1 minutes with a flow rate of 0.4 mL/min. Chromatograms were collected monitoring the column effluent at 236 nm with a UV/Vis detector and with a Single-Quadrapole (QDa) mass spectrometer set to monitor a mass range of 50-1200 Da.
- QDa Single-Quadrapole
- Samples were: EPE001 filtered at ⁇ 80° C. through an 11 ⁇ m qualitative filter (H3a), EPE001 filtered at ⁇ 80° C. through a 0.2 ⁇ m filter (H3b), EPE001 cooled to room temperature before filtration through an 11 ⁇ m qualitative filter (A3a), and EPE001 cooled to room temperature before filtration through a 0.2 ⁇ m filter (A3b).
- FIGS. 4 and 5 are treatments of human breast cancer cells treated with an exemplary product of the extraction process (EPE001).
- EPE001 20,000 MCF7 (human breast adenocarcinoma) cells were seeded in 48 well plates in triplicate, allowed to adhere for 24 hours before treatment commenced (Day 0).
- Treatment groups were each performed in triplicate and include: untreated control group (UNT), treated with EPE001 filtered at ⁇ 80° C. through an 11 ⁇ m qualitative filter (HQ), treated with EPE001 filtered at ⁇ 80° C.
- FIG. 4 shows the results in the form of a bar graph of applying each of the four filtered versions of EPE001 to MCF7 cells which are cultured human breast cancer cells.
- Control group samples that received no treatment rose from 20,000 cells at day 0 to nearly 300,000 cells by the end of day 5.
- All applications of the example extract have a statistically significant (ANOVA p-value ⁇ 0.05) impact on the growth of the cancer cells.
- EPE001 filtered with the qualitative (11 ⁇ M) filter at 80° C. had the greatest cytotoxic effect, decreasing the original cell count by 28-fold in comparison to a 14 ⁇ increase in cell count for the control group. Extract treated cancer cells not only showed strong cytotoxic effects, but also displayed an effect on the morphology of the cells as shown in FIG.
- Treated cancer cells show changes in cell membrane permeability, diameter, volume and shape (rounder) as well as becoming less adherent to the microplate surface—suggesting multiple mechanisms of action resulting in cytotoxicity. Arrows indicate condensed cytoplasmic constituents, loss of membrane integrity and cell-cell as well as cell-substrate adhesion. When comparing the UNT cells to EPE001 treated samples, it is evident that there is significant cell loss. Furthermore, where the UNT cells look smooth and very confluent, cytoplasmic extension, stress and cell death features such as vacuolization and membrane blebbing.
- FIG. 6 and FIG. 7 are treatments of healthy human epithelial cells with an exemplary product of the extraction process (EPE001).
- EPE001 exemplary product of the extraction process
- 20,000 MCF10A normal, human mammary epithelial cells were seeded in 48 well plates in triplicate, allowed to adhere for 24 hours before treatment commenced (Day 0).
- Treatment groups were each performed in triplicate and include: untreated control group (UNT), treated with EPE001 filtered at ⁇ 80° C. through an 11 ⁇ m qualitative filter (HQ), treated with EPE001 filtered at ⁇ 80° C.
- UNT untreated control group
- HQ 11 ⁇ m qualitative filter
- FIG. 6 shows the results in the form of a bar graph of applying each of the four filtered versions of EPE001 were applied to MCF10A cells which are cultured human normal epithelial breast cells. Control group samples that received no treatment rose from 20,000 cells at Day 0 to ⁇ 40,000 cells by the end of day 5. It should be noted that normal mammary epithelial cells grow more slowly and are constrained by area and cell-cell interactions whereas cancer cells grow much faster and are not constrained either by confluence or cell-cell boundaries. EPE001 filtered with the 0.2 ⁇ m filter at 80° C. did not have a statistically significant change in cell count by the end of day 5 (ANOVA p-value >0.05, meaning there is no statistical significance in the comparison).
- FIG. 8 shows the results in the form of a bar graph of applying each of the four filtered versions of EPE001 were applied to HFF1 cells which are cultured human normal foreskin fibroblast cells. Control group samples that received no treatment proliferated from 20,000 cells at day 0 to ⁇ 45,000 cells by the end of day 5. It should be noted that normal fibroblast cells grow more slowly and are constrained by area and cell-cell interactions whereas cancer cells grow much faster and are not constrained either by confluence or cell-cell boundaries. EPE001 filtered with the 0.2 ⁇ m filter at 80° C. did not have a statistically significant change in cell count by the end of day 5 (ANOVA p-value >0.05, meaning there is no statistical significance in the comparison).
- RNA-Seq analysis or Whole Transcriptome Shotgun Sequencing uses a Next-Generation Sequencing (NGS) method to catalog and count the number of RNA transcripts produced in a selected cell culture.
- NGS Next-Generation Sequencing
- This technique can be used as a comparative tool to determine which genes are activated or suppressed and to what degree in different environments—in this example, with and without the presence of the Extract Product.
- Data collected from RNA-Seq analysis is analyzed utilizing a web-based software application, Ingenuity Pathway Analysis (IPA), produced by QIAGEN Bioinformatics.
- IPA Ingenuity Pathway Analysis
- FIG. 10 is a summary of gene expression changes in the presence of an exemplary product of the extraction process (EPE001) using RNA-Seq analysis.
- MCF7 human breast adenocarcinoma
- MCF7 human breast adenocarcinoma
- Cells were seeded at 1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 cells in T25 flasks and incubated at 37° C., 5% C02 for 24 hours. Cells were allowed to adhere for 24 hours before treatment commenced. Cells were treated with medium only (reference sample) or treated with EPE001 and allowed to incubate for 24 hours. Cells were harvested and RNA was isolated using a Qiagen RNeasy Mini Kit as per manufacturer instruction. RNA transcriptome was sequenced using an Illumina MiSeq system.
- FASTQ files were generated by the Illumina CASAVA v1.8.2 and the quality of reads was evaluated by NGSQC Toolkit v2.3. High-quality reads were mapped, annotated to exons, and normalized to FPKM values for all 25,278 human RNA references in NCBI RefSeq database. Differential gene expression analysis was determined using DNAstar software. Biological pathway analyses were carried out using Ingenuity Pathway Analysis (Qiagen).
- FIG. 10 represents the IPA software output of genes upregulated (increase in the physical number of RNA transcripts produced for a particular gene) or downregulated (decrease in the physical number of RNA transcripts produced for a particular gene) in the presence of the Extract Product.
- HGF hepatocyte growth factor
- VEGF vascular endothelial growth factor
- HSPG2 heparan sulfate proteoglycan 2
- TP53 tumor protein 53
- TP53 tumor protein 53
- NUPR1 nuclear protein 1
- TP53 a tumor suppressor gene. This gene is upregulated in the presence of EPE001.
- RNA-Seq analysis coincides with the physical results seen in FIGS. 4 and 5 .
- FIG. 11 is a summary of diseases and associated networks that are affected as a result in upregulation or downregulation of the summary from the RNA-Seq analysis. This output represents the top scoring diseases and networks as determined by the Ingenuity Pathway Analysis (Qiagen) software package.
- Qiagen Ingenuity Pathway Analysis
- EPE001 Treatment of cancer cells with EPE001 resulted in over 2000 molecules that were upregulated or downregulated, many of which are involved in tumor suppression and inhibition of cell growth. Outside of cancer related networks, EPE001 also had an effect on genes associated with DNA replication, recombination and repair, embryonic development, nervous system development and function. These results would suggest an increase in stimulation of healing, stem cell activity, as well as stimulation of hair growth.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The preparation of an aqueous extract resulting from an aqueous extraction process of Cinnamomum aromaticum, Arctium lappa, Viticis fructus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare and the chemical composition comprising said extract or fraction thereof, and the use of said composition or fraction thereof for treating or preventing cancers and inflammation related diseases, hair loss, stimulating hair growth, increasing energy production, and boosting immunity.
Description
- This application is a Continuation of and claims priority in U.S. Non-Provisional patent application Ser. No. 16/590,807 Filed Oct. 2, 2019, which is a Non-Provisional of U.S. Provisional Patent Application 62/740,047 Filed Oct. 2, 2018 and is related to U.S. Non-Provisional patent application Ser. No. 16/686,535, filed Nov. 18, 2019, all of which is incorporated herein by reference.
- The present invention relates generally to an aqueous extraction process and method for use thereof, and more specifically to an aqueous extraction process of specific plants for the chemical composition thereof.
- Existing methods for extracting key compounds or components for generating a chemical composition comprised of an extract thereof do exist. However, these processes have failed to adequately and reliably produce a chemical composition having the results of the present invention.
- Heretofore there has not been available a system or method for an aqueous extraction process and resulting extract with the advantages and features of the present invention.
- The present invention generally provides for the preparation of an aqueous extract resulting from an aqueous extraction of individual or mixtures of Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare and the chemical composition comprising said extracts or fractions thereof, and the use of said compositions or fractions thereof for treating or preventing cancers and inflammation related diseases, hair loss, stimulating hair growth, increasing energy production, and boosting immunity.
- The resulting extracts include a mixture of naturally occurring biologically active phytochemical compounds that possess a variety of beneficial animal and human health effects.
- The drawings constitute a part of this specification and include exemplary embodiments of the present invention illustrating various objects and features thereof.
-
FIG. 1 is a diagram of a preferred embodiment static (batch) aqueous extraction system. -
FIG. 2 is a diagram of an alternative embodiment dynamic (semi-continuous flow) aqueous extraction system. -
FIG. 3 is a LC-MS chromatogram depicting the components of an exemplary product (EPE001) of an extraction process utilizing one of the embodiments of the extraction systems ofFIGS. 1 and 2 . -
FIG. 4 is a bar graph depicting results of a treatment of human breast cancer cells utilizing a product produced by the process resulting from the embodiments of eitherFIG. 1 orFIG. 2 . -
FIG. 5 shows a series of cells taken through a microscope onday 5 of the bar graph ofFIG. 4 . -
FIG. 6 is a bar graph depicting results of a treatment of human epithelial cells utilizing a product produced by the process resulting from the embodiments of eitherFIG. 1 orFIG. 2 . -
FIG. 7 shows a series of cells taken through a microscope onday 5 of the bar graph ofFIG. 6 . -
FIG. 8 is a bar graph depicting results of a treatment of fibroblast cells utilizing a product produced by the process resulting from the embodiments of eitherFIG. 1 orFIG. 2 . -
FIG. 9 shows a series of cells taken through a microscope onday 5 of the bar graph ofFIG. 8 . -
FIG. 10 is a table including a summary of gene expression changes in the presence of an exemplary product of the extraction process (EPE001) using RNA-Seq analysis. -
FIG. 11 is a table including a summary of diseases and associated networks that are affected as a result in upregulation or downregulation of the summary from the RNA-Seq analysis. - As required, detailed aspects of the present invention are disclosed herein, however, it is to be understood that the disclosed aspects are merely exemplary of the invention, which may be embodied in various forms. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art how to variously employ the present invention in virtually any appropriately detailed manifestation.
- Certain terminology will be used in the following description for convenience in reference only and will not be limiting. For example, up, down, front, back, right and left refer to the invention as orientated in the view being referred to which the referral is directed. The words, “inwardly” and “outwardly” refer to directions toward and away from, respectively, the geometric center of the aspect being described and designated parts thereof. Forwardly and rearwardly are generally in reference to the direction of travel, if appropriate. Said terminology will include the words specifically mentioned, derivatives thereof and words of similar meaning.
-
FIG. 1 shows a staticaqueous extraction system 2. A process utilizing thisstatic system 2 results in a product capable of producing desired results as described in more detail and in specific examples below. - Individual or a desired mixture of Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare are combined in equal or various amounts by dry weight and placed in a spunbond
nonwoven fabric container 14. The fabric container may be placed upon apedestal 16 within theextraction apparatus 8 for optimal results. The spunbondnonwoven fabric container 14 is sealed and then fixed within theextraction apparatus 8 containing reverse-osmosis membrane filtered purified or distilledwater 10 as shown inFIG. 1 . The extraction apparatus may be made of a stainless steel or glass vessel. Theextraction apparatus 8 is contained within aheating element 6. The extraction apparatus is closed and sealed with aseal 12 and then heated such that thewater 10 is boiling for 3-6 hrs. Some of the vapor is discharged through the water-cooledcondenser outlet 4 affixed to the top of theextraction apparatus 8 allowing some volatiles to escape while retaining a portion that are condensed and returned to the extraction apparatus. The seal retains thecondenser unit 4 in connection with theextraction apparatus 8. The resulting extraction mixture is then filtered in succession using a membrane filter with a pore size not bigger than 10-6 m (1 micron) and purified water at 90-100° C., 70-85° C., 40-60° C., 15-30° C., and 5-15° C., providing the final product filtrate (extract) that contains ˜370 mg of biologically active solid ingredients per liter of aqueous extract. Example compounds identified in the aqueous extract include acids such a chlorogenic and cinnamic acid, aldehydes, e.g. cinnamaldehyde and lignans, e.g. archin. - For example, by dry weight, for each liter of water, 220 mg of Cinnamomum cassia, 110 mg Arctium lappa, 220 mg Vitex agnus castus, 110 mg Lonicera japonica, 110 mg Acanthopanax gracilistylis, 110 mg Raphanus sativus, 110 mg Astragalus membranaceus and 220 mg Hordeum vulgare are combined and placed in a spunbond nonwoven fabric, and the spunbond nonwoven fabric sealed and then fixed within the extraction apparatus filled with reverse-osmosis membrane filter purified or distilled water. The extraction vessel is closed and then heated to boiling for 3 hrs. Some of vapor is discharged through the water-cooled condenser outlet affixed to the top of the extraction vessel allowing a portion of volatiles to escape while retaining some that are condensed and returned to the extraction vessel. The resulting hot extraction mixture, of these ingredients is referred to as, EPE001, from this point onward, is then filtered in succession via simple vacuum assisted filtration using membrane filters with a pore size not bigger than 10-6 m (1 micron) at 90-100° C., 70-85° C., 40-60° C., 15-30° C., and 5-15° C. providing the final product extract that contains ˜370 mg of biologically active solid ingredients per liter of aqueous extract.
-
FIG. 2 presents an alternative system for producing a chemical compound from an aqueous extraction process utilizing adynamic system 52. In the same manner as thestatic system 2, an individual herb or a desired mixture of Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare, are combined in equal or various amounts by dry weight and placed in a spunbondnonwoven fabric container 14, and the spunbondnonwoven fabric container 14 is sealed and then fixed within theextraction vessel 8. Reverse-osmosis membrane filter purified, or distilledwater 10 is then pumped into theextraction vessel 8 via apump 20. Theextraction apparatus 8 is contained within aheating element 6. The extraction apparatus is closed and sealed with aseal 12 and heated to boiling for 4-6 hrs. Some of the vapor is discharged through the water-cooledcondenser outlet 4 affixed to the top of the extraction vessel allowing some volatiles to escape while retaining some that are condensed and returned to the extraction vessel. The resulting extraction mixture, EPE001, is then filtered in succession by pressure driven filtration using filters with a pore size not bigger than 10-6 m (1 micron) utilizing a system of appropriately connected pumps and valves that allow for efficient transfer of the purified water extract at 70-95° C., followed by filtering the extract using purified water at 70-95° C., 40-60° C., 15-30° C., and 5-15° C., providing the final product extract that contains ˜350 mg of active solid ingredients per liter of aqueous extract. This extraction process allows for a dynamic semi-continuous flow production of biologically active extract by pausing the process, recharging the spunbond nonwoven fabric with selected amounts of dried herbs and initiating the process by pumping purifiedwater 10 into theextraction vessel 8 and restarting the heating device. - This process is made dynamic through the use of a large vessel of purified
water 18 which is pumped using apump 20 into theextraction vessel 8. It is then pulled out of theextraction vessel 8 using a series ofvalves 22, filters 24, and pumps 20 as shown inFIG. 2 into one ormore storage containers 26, 26.1, 26.2, 26.3. The system can be run dynamically until all storage containers are filled, and as soon as there is volume in one storage container as shown, the aqueous extraction can pass onto the next pump and filter set. Purified water can be pumped into thevessel 8 from thereservoir 18 through an inlet in the reservoir near the top of the vessel. After the boiling step is complete, the aqueous extract can be pumped out through an outlet near the bottom of the vessel and through a single or series of decreasing pore-size filters with the final filter being a 0.2 μm filter. The filtrate would then be dispensed into a collection vessel as a finished product for a number of various uses. - The use of the extract resulting from the aqueous extraction processes as described herein are varied. A first use of the extract would be as a potential cancer therapeutic. This would provide an application to a broad range of solid cancers (neoplasias) due to effects of the extract chemical composition on mitochondrial function in cancer cells (e.g. apoptosis, autophagy, and mitochondrial membrane potential changes) as well as changes in transcriptional activation (promote or inhibit) of key genes associated with cancer progression or suppression. The benefits include a reduction or elimination of side effects common in existing cancer therapeutics. The preparation of the extract as presented herein provides for the delivery of biologically active compounds topically or as an aqueous oral dose. It has a bioactivation and bioavailability increase upon digestion associated with changes in pH. It causes a decrease in the proliferation of cancer cells and an inhibition of genes related to cancer cell growth.
- A second use of the extract as presented herein would be an anti-inflammatory therapeutic. It provides a reduction in reactive oxygen species formation in normal cells. It reduces production of inflammatory cytokines. It also provides increased mobility with concurrent decrease in joint pain.
- A third use is as an energy supplement. The extract provides an increase in beta-oxidation utilizing fatty acids as a substrate for generation of ATP. It provides increased energy production (e.g. mitochondrial efficiency). It also provides a decrease in glucose dependency as a metabolic substrate, while also reducing inflammation as described above.
- A fourth use is as a weight loss supplement. The extract has been shown to increase beta-oxidation utilizing fatty acids as a substrate for generation of ATP. and a decrease in glucose dependency as a metabolic substrate. The extract has also been shown to decrease glucose dependency as a metabolic substrate. These metabolic changes are expected to cause weight loss. The extract has also been shown to provide an inhibition of some known obesity related gene expression.
- A fifth use is for its antiviral effectiveness due to increased potential cell membrane resistance and decreased replication capabilities against clinically relevant viral strains including HIV, Influenza Virus, West Nile Virus, Adenovirus, and Polymavirus.
- A sixth use is for its antimicrobial effectiveness due to its effectiveness against pathogenic bacterial infections including, Streptococcus sp., Staphylococcus sp., and Listeria sp.
- A seventh use is for dermatological stem cell activity, such as for use for hair growth or other uses against skin conditions such as atopic dermatitis, psoriasis, and eczema.
- An eighth use is for boosting the immune system. Specifically, inducing pluripotent stem cells to replace depleted populations of T-cell lymphocytes. This population replenishment has direct positive benefits in the mechanism of action and is described in [0027] and [0028].
-
FIGS. 3-9 show several examples and results thereof utilizing a product produced by the processes described above. Other examples are not explicitly shown, but the results are described below. Typical treatments for cancer involve chemicals that are not only toxic to infected cells but also other surrounding cells, tissues and systems. Because of this there is a growing need and interest for utilizing natural products for treatment of a variety of human diseases and conditions. Using the herein described process, a reproducible, aqueous extract of a combination of plants has been shown to be toxic to human cultured cancer cells but does not harm healthy cells. - In these examples, each of the eight herbs (Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare) were milled to a powder then passed through a 0.21 mm mesh sieve to exclude any large particulates. The powders were combined and placed into a spunbond nonwoven fabric bag and sealed then placed into a vessel containing reverse-osmosis purified water utilizing the
static system 2 shown inFIG. 1 and alternatively the dynamiccontinuous system 52 shown inFIG. 2 . After the vessel was sealed, the water was brought to a boil for 3 hours. The aqueous extract (EPE001) was split into four aliquots. Two aliquots were cooled to 80° C. before passing through either a qualitative filter (11 μm) or a 0.2 μm filter. The other two aliquots were allowed to cool to room temperature before being passed through either a qualitative filter (11 μm) or a 0.2 μm filter. A portion of each aliquot was lyophilized to dryness before being diluted with purified water to a final concentration of 3.6 mg extract residue per milliliter. Each of these samples were then utilized in analytical experimentation and bioassays to determine chemical composition and biological activity -
FIG. 3 shows a graph wherein each of the four samples were analyzed using a Waters ACQUITY UPLC-PDA-MS system. Major components were identified by mass, then verified through comparison to a prepared standard of the isolated molecule to confirm the identity. Major components of the extract are: arctigenin, cholorgenic acid, neocholorgenic acid, isochlorogenic acid A, arctiin, quercetin 3-O-β-D glucoside, cyanarin and casticin. Other components of the extract have not yet been identified. Sample collected from the extraction process was lyophilized to dryness and resuspended to a final concentration of 3.6 mg/mL in 0.1% formic acid (pH 4.2). Chromatography was achieved using a 20 μL injection volume and a Waters ACQUITY UPLC HSS T3, 100 Å, 2.1×100 mm, column. A gradient elution was used with Mobile Phase A of 0.1% formic acid (pH 4.2) and Mobile Phase B of 80:20 acetonitrile: water. The linear chromatographic gradient started with 95% Mobile Phase A and concluded with 5% Mobile Phase A over 19.1 minutes with a flow rate of 0.4 mL/min. Chromatograms were collected monitoring the column effluent at 236 nm with a UV/Vis detector and with a Single-Quadrapole (QDa) mass spectrometer set to monitor a mass range of 50-1200 Da. Samples were: EPE001 filtered at ˜80° C. through an 11 μm qualitative filter (H3a), EPE001 filtered at ˜80° C. through a 0.2 μm filter (H3b), EPE001 cooled to room temperature before filtration through an 11 μm qualitative filter (A3a), and EPE001 cooled to room temperature before filtration through a 0.2 μm filter (A3b). -
FIGS. 4 and 5 are treatments of human breast cancer cells treated with an exemplary product of the extraction process (EPE001). 20,000 MCF7 (human breast adenocarcinoma) cells were seeded in 48 well plates in triplicate, allowed to adhere for 24 hours before treatment commenced (Day 0). Treatment groups were each performed in triplicate and include: untreated control group (UNT), treated with EPE001 filtered at ˜80° C. through an 11 μm qualitative filter (HQ), treated with EPE001 filtered at ˜80° C. through a 0.2 μm filter (H.2), treated with EPE001 cooled to room temperature before filtration through an 11 μm qualitative filter (CQ), and treated with EPE001 cooled to room temperature before filtration through a 0.2 μm filter (C.2). Cells were photographed and counted every 24 hours for 5 days. Images atDay 5 are represented inFIG. 5 . -
FIG. 4 shows the results in the form of a bar graph of applying each of the four filtered versions of EPE001 to MCF7 cells which are cultured human breast cancer cells. Control group samples that received no treatment (UNT) rose from 20,000 cells atday 0 to nearly 300,000 cells by the end ofday 5. All applications of the example extract have a statistically significant (ANOVA p-value <0.05) impact on the growth of the cancer cells. Byday 5, EPE001 filtered with the qualitative (11 μM) filter at 80° C. had the greatest cytotoxic effect, decreasing the original cell count by 28-fold in comparison to a 14× increase in cell count for the control group. Extract treated cancer cells not only showed strong cytotoxic effects, but also displayed an effect on the morphology of the cells as shown inFIG. 5 . Treated cancer cells show changes in cell membrane permeability, diameter, volume and shape (rounder) as well as becoming less adherent to the microplate surface—suggesting multiple mechanisms of action resulting in cytotoxicity. Arrows indicate condensed cytoplasmic constituents, loss of membrane integrity and cell-cell as well as cell-substrate adhesion. When comparing the UNT cells to EPE001 treated samples, it is evident that there is significant cell loss. Furthermore, where the UNT cells look smooth and very confluent, cytoplasmic extension, stress and cell death features such as vacuolization and membrane blebbing. - Similarly,
FIG. 6 andFIG. 7 are treatments of healthy human epithelial cells with an exemplary product of the extraction process (EPE001). 20,000 MCF10A (normal, human mammary epithelial) cells were seeded in 48 well plates in triplicate, allowed to adhere for 24 hours before treatment commenced (Day 0). Treatment groups were each performed in triplicate and include: untreated control group (UNT), treated with EPE001 filtered at ˜80° C. through an 11 μm qualitative filter (HQ), treated with EPE001 filtered at ˜80° C. through a 0.2 μm filter (H.2), treated with EPE001 cooled to room temperature before filtration through an 11 μm qualitative filter (CQ), and treated with EPE001 cooled to room temperature before filtration through a 0.2 μm filter (C.2). Cells were photographed and counted every 24 hours for 5 days Images atDay 5 are represented inFIG. 7 . -
FIG. 6 shows the results in the form of a bar graph of applying each of the four filtered versions of EPE001 were applied to MCF10A cells which are cultured human normal epithelial breast cells. Control group samples that received no treatment rose from 20,000 cells atDay 0 to ˜40,000 cells by the end ofday 5. It should be noted that normal mammary epithelial cells grow more slowly and are constrained by area and cell-cell interactions whereas cancer cells grow much faster and are not constrained either by confluence or cell-cell boundaries. EPE001 filtered with the 0.2 μm filter at 80° C. did not have a statistically significant change in cell count by the end of day 5 (ANOVA p-value >0.05, meaning there is no statistical significance in the comparison). - Cells treated with the 0.2 μm filtered EPE001 did not show morphological differences, as shown in
FIG. 7 , from untreated cells. Cells treated with the qualitative filter (11 μM) EPE001 did show slight morphological differences with some cytotoxicity. Additionally, cells treated with EPE001 became more adherent to the walls of the microplate, which may account for some of the cell count differences between treated cells and the untreated control samples. Given that epithelial cells serve as barriers for the body, this adherent property was considered beneficial -
FIG. 8 shows the results in the form of a bar graph of applying each of the four filtered versions of EPE001 were applied to HFF1 cells which are cultured human normal foreskin fibroblast cells. Control group samples that received no treatment proliferated from 20,000 cells atday 0 to ˜45,000 cells by the end ofday 5. It should be noted that normal fibroblast cells grow more slowly and are constrained by area and cell-cell interactions whereas cancer cells grow much faster and are not constrained either by confluence or cell-cell boundaries. EPE001 filtered with the 0.2 μm filter at 80° C. did not have a statistically significant change in cell count by the end of day 5 (ANOVA p-value >0.05, meaning there is no statistical significance in the comparison). - Cells treated with EPE001 filtered with the 0.2 μm filter at 80° C. did not show morphological differences in comparison to the untreated control group as shown in
FIG. 9 . However, the other filtration versions of EPE001 showed loss of cells, increased cell size and more strongly delineated boundaries. As with the epithelial cells, fibroblast cells treated with EPE001 became more adherent to the walls of the microplate, which may account for some of the cell count differences between treated cells and the untreated control samples. In this case, stronger adherence is positive attribute, especially since fibroblast cells comprise the structural framework of connective tissues and play key roles in wound healing. - RNA-Seq analysis or Whole Transcriptome Shotgun Sequencing (WTSS) uses a Next-Generation Sequencing (NGS) method to catalog and count the number of RNA transcripts produced in a selected cell culture. This technique can be used as a comparative tool to determine which genes are activated or suppressed and to what degree in different environments—in this example, with and without the presence of the Extract Product. Data collected from RNA-Seq analysis is analyzed utilizing a web-based software application, Ingenuity Pathway Analysis (IPA), produced by QIAGEN Bioinformatics.
-
FIG. 10 is a summary of gene expression changes in the presence of an exemplary product of the extraction process (EPE001) using RNA-Seq analysis. MCF7 (human breast adenocarcinoma) cells were seeded at 1×10{circumflex over ( )}6 cells in T25 flasks and incubated at 37° C., 5% C02 for 24 hours. Cells were allowed to adhere for 24 hours before treatment commenced. Cells were treated with medium only (reference sample) or treated with EPE001 and allowed to incubate for 24 hours. Cells were harvested and RNA was isolated using a Qiagen RNeasy Mini Kit as per manufacturer instruction. RNA transcriptome was sequenced using an Illumina MiSeq system. FASTQ files were generated by the Illumina CASAVA v1.8.2 and the quality of reads was evaluated by NGSQC Toolkit v2.3. High-quality reads were mapped, annotated to exons, and normalized to FPKM values for all 25,278 human RNA references in NCBI RefSeq database. Differential gene expression analysis was determined using DNAstar software. Biological pathway analyses were carried out using Ingenuity Pathway Analysis (Qiagen). - For this example, untreated MCF7 breast cancer cells were used as a control. The differences between this control and the MCF7 breast cancer cells treated with EPE001 (filtered at 80° C. with a 0.2 μm filter) using RNA-Seq analysis.
FIG. 10 above represents the IPA software output of genes upregulated (increase in the physical number of RNA transcripts produced for a particular gene) or downregulated (decrease in the physical number of RNA transcripts produced for a particular gene) in the presence of the Extract Product. - The gene, HGF (hepatocyte growth factor), is involved in cell growth and has higher expression in cancer cells. This gene is downregulated in the presence of EPE001.
- The gene, VEGF (vascular endothelial growth factor), has been implicated in promoting blood supply to cancer cells and the metastatic cascade. This gene is downregulated in the presence of EPE001.
- The gene, HSPG2 (heparan sulfate proteoglycan 2), is involved in angiogenesis, β-amyloid binding, abnormal morphology and cell proliferation. This gene is also downregulated in the presence of EPE001.
- The gene, TP53 (tumor protein 53), is a well-studied tumor suppressor gene that is involved in regulation of cell death and prevention of proliferation. This gene is upregulated in the presence of EPE001.
- The gene, NUPR1 (nuclear protein 1), regulates cell death and signals TP53, which is a tumor suppressor gene. This gene is upregulated in the presence of EPE001.
- In summary, important upstream regulator genes associated with cancer proliferation are downregulated in the presence of the Extract Product. Important upstream master tumor suppressor genes are upregulated in the presence of EPE001. The RNA-Seq analysis coincides with the physical results seen in
FIGS. 4 and 5 . -
FIG. 11 is a summary of diseases and associated networks that are affected as a result in upregulation or downregulation of the summary from the RNA-Seq analysis. This output represents the top scoring diseases and networks as determined by the Ingenuity Pathway Analysis (Qiagen) software package. - Additionally, treatment of cancer cells with EPE001 resulted in over 2000 molecules that were upregulated or downregulated, many of which are involved in tumor suppression and inhibition of cell growth. Outside of cancer related networks, EPE001 also had an effect on genes associated with DNA replication, recombination and repair, embryonic development, nervous system development and function. These results would suggest an increase in stimulation of healing, stem cell activity, as well as stimulation of hair growth.
- There was also an upregulation in genes associated with lipid metabolism which would suggest EPE001 would increase lipid metabolism. This has negative effects on cancer cells because they rely on carbohydrate metabolism for proliferation. This phenomenon also suggests that energy output would increase in healthy cells when using lipid substrates rather than carbohydrates because the process of β-oxidation yields ˜4× as much energy as aerobic respiration (glucose-dependent).
- It is to be understood that while certain embodiments and/or aspects of the invention have been shown and described, the invention is not limited therein and encompasses various other embodiments and aspects.
Claims (8)
1. A method of producing an aqueous extract for treatments, the method comprising the steps:
a) placing a dry mixture within a fibrous container, said dry mixture consisting of: Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare;
b) placing said fibrous container within an extraction vessel;
c) filling said extraction vessel with a volume of water;
c) heating said volume of water with a heating element about said extraction vessel such that draw volatiles, water vapor, and an extraction mixture are generated from said dry mixture within said volume of water;
e) removing said water vapor with a condensing unit connected to said extraction vessel; and
f) filtering said extraction mixture out of said extraction vessel.
2. The method of claim 1 , further comprising the step:
mixing 220 mg of Cinnamomum cassia, 110 mg Arctium lappa, 220 mg Vitex agnus castus, 110 mg Lonicera japonica, 110 mg Acanthopanax gracilistylis, 110 mg Raphanus sativus, 110 mg Astragalus membranaceus and 220 mg Hordeum vulgare for each liter of said volume of water to create said dry mixture.
3. The method of claim 2 , further comprising the step of treating human breast cancer cells with said extraction mixture.
4. The method of claim 2 , further comprising the step of treating human epithelial cells with said extraction mixture.
5. The method of claim 2 , further comprising the step of treating human fibroblast cells with said extraction mixture.
6. The method of claim 2 , further comprising the step treating a condition selected from a list consisting of cancer; inflammation; fatigue; obesity; viral infections; microbial infections; hair loss; stimulation of dermatological stem cell activity for skin conditions; and boosting the immune system, comprising administering an effective amount of the composition produced through the method of claim 1 .
7. The method of claim 6 , wherein said treatment is presented in a form selected from a list consisting of: topical; ingestible; and intravenously.
8. A method of treating a condition selected from a list consisting of: wounds, scarring, burns, itching, rashes or irritations, and cosmetic purposes, comprising administering an effective amount of the composition of claim 1 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/115,927 US20230201294A1 (en) | 2018-10-02 | 2023-03-01 | Aqueous extraction process of plants, method thereof, and product by process |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862740047P | 2018-10-02 | 2018-10-02 | |
US16/590,807 US11622987B2 (en) | 2018-10-02 | 2019-10-02 | Aqueous extraction process of plants, method thereof, and product by process |
US18/115,927 US20230201294A1 (en) | 2018-10-02 | 2023-03-01 | Aqueous extraction process of plants, method thereof, and product by process |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/590,807 Continuation US11622987B2 (en) | 2018-10-02 | 2019-10-02 | Aqueous extraction process of plants, method thereof, and product by process |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230201294A1 true US20230201294A1 (en) | 2023-06-29 |
Family
ID=69946990
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/590,807 Active US11622987B2 (en) | 2018-10-02 | 2019-10-02 | Aqueous extraction process of plants, method thereof, and product by process |
US18/115,927 Pending US20230201294A1 (en) | 2018-10-02 | 2023-03-01 | Aqueous extraction process of plants, method thereof, and product by process |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/590,807 Active US11622987B2 (en) | 2018-10-02 | 2019-10-02 | Aqueous extraction process of plants, method thereof, and product by process |
Country Status (1)
Country | Link |
---|---|
US (2) | US11622987B2 (en) |
-
2019
- 2019-10-02 US US16/590,807 patent/US11622987B2/en active Active
-
2023
- 2023-03-01 US US18/115,927 patent/US20230201294A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200101126A1 (en) | 2020-04-02 |
US11622987B2 (en) | 2023-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Cordyceps cicadae polysaccharides inhibit human cervical cancer hela cells proliferation via apoptosis and cell cycle arrest | |
CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
Kim et al. | Panax notoginseng inhibits tumor growth through activating macrophage to M1 polarization | |
WO2023065860A1 (en) | Method for extracting phenolic glycosides from lamiophlomis rotata and use of phenolic glycosides in preparation of drugs for preventing and treating hepatic fibrosis or in health care products | |
CN103751279A (en) | Preparation method of anti-bacteria schisandra chinensis extractive | |
Welch et al. | Investigation of Moringa oleifera leaf extract and its cancer-selective antiproliferative properties | |
CN104472363B (en) | Promote rosmarinic acid and the revulsion of salvianolic acid B accumulation in Hairy Root Cultures of Salvia miltiorrhiza | |
US20230201294A1 (en) | Aqueous extraction process of plants, method thereof, and product by process | |
Han et al. | In vitro anti-tumor activity in SGC-7901 human gastric cancer cells treated with dandelion extract | |
Afolayan et al. | Ultrastructure and elemental analysis of Hypoxis hemerocallidea: a multipurpose medicinal plant | |
Yang et al. | Nephroprotective effects of Isaria felina in rats with adenine-induced chronic renal failure | |
CN1126539C (en) | Application of tanshinone in preparing medicine for treating tumor | |
CN102100737A (en) | Medicinal composition containing general ginsenoside and total salvianolic acid and preparation method thereof | |
TWI555529B (en) | A use of an herbal extract for manufacturing drugs against liver cancer | |
CN103330781A (en) | Traditional Chinese medicine composite with anti-tumor effect and preparation method of injection of same | |
Larypoor | Investigation of HER-3 gene expression under the influence of carbohydrate biopolymers extract of shiitake and reishi in MCF-7 cell line | |
CN108969580B (en) | Preparation method and application of blue cloth total tannin | |
Lee et al. | Anti-cancer Activities of Ginseng Extract Fermented with Phettinus linteus | |
CN101953857A (en) | Compound fermented cordyceps sinensis bacterium powder (paecilomyces hepiali Cs-4 bacterium powder) composite medicine | |
CN102119956A (en) | Application of lignum dalbergiae odoriferae oil in preparing medicament for resisting human pathogenic bacteria and lignum dalbergiae odoriferae perfume | |
CN100518802C (en) | Extraction of effective parts for Danshen root and rhizoma chuanxiong | |
Kang et al. | Porphyra tenera extracts have immune stimulation activity via increasing cytokines in mouse primary splenocytes and RAW264. 7 macrophages | |
US20230201296A1 (en) | Topical cream-based cosmetic and wound healing formulations and methods of use | |
US20200197475A1 (en) | Topical cream-based cosmetic and wound healing formulations and methods of use | |
CN109820879A (en) | Antrodia camphorata extract, the preparation method of Antrodia camphorata composition and medical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EIR PHARMACEUTICALS, LLC, KANSAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUNCAN, WILLIAM P;GOLLAHON, LAUREN S;PUTNAM, WILLIAM C;SIGNING DATES FROM 20191003 TO 20191015;REEL/FRAME:062842/0284 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |